Home | By sponsor

CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title Date of Registration State
Racotumomab-alum cancer vaccine for solid tumors in pediatric patients 15/12/2015 Registered
Vaxira as adjuvant treatment for non-small cell lung cancer 15/12/2015 Registered
EC122 HER-1 Prostate Phase I 15/11/2016 Registered
CIMAvax-EGF vaccine Predictor Phase IV 14/12/2015 Registered
NGcGM3/VSSP and nimotuzumab in patients with triple negative breast cancer 12/10/2016 Registered
Treatment of SARS CoV-2 pneumonia with the anti-CD6 monoclonal antibody itolizumab 12/05/2020 Registered
CIMAvax-EGF in Bladder cancer 11/08/2020 Registered
Racotumomab vaccine- Lung Cancer- Adults-predictors of response - Exploratory 09/07/2018 Registered
Itolizumab for Moderate-to-Severe Psoriasis-phase 3 08/10/2015 Registered
VSSP in metastasic renal cell carcinoma 08/08/2018 Registered
Racotumomab-alum for recurrent platimun-sensitive epithelial ovarian cancer 08/07/2015 Registered
NGcGM3/VSSP in small cell lung cancer 07/12/2016 Registered
NGcGM3/VSSP in Metastatic melanoma 07/12/2016 Registered
14F7 in chronic B-cell lymphoproliferative syndrome 07/03/2018 Registered
RituxCIM in relapsed or refractory indolent B-cell non-Hodgkin lymphoma 05/11/2013 Registered
Nimotuzumab cold kit for the immunodiagnosis of solid tumors 05/10/2018 Registered
CIMAbior® in CD20-positive B-cell Non-Hodgkin Lymphoma 05/09/2017 Registered
CIMAVax EGF in Lung Cancer in PHC. Phase IV 05/08/2014 Registered
Dose scale-up and cohort expansion with the therapeutic mAb 14F7 04/12/2015 Registered
Vaccine HER1 / VSSP for prostate cancer, head and neck carcinoma and advanced colon cancer . Phase I 03/11/2017 Registered